SecProbe.io

CORRESP
1
filename1.htm

SEC Response Letter

 November 26, 2014

VIA EDGAR AND FEDERAL EXPRESS

 Division of
Corporation Finance

 United States Securities and Exchange Commission

100 F Street, NE

 Washington, D.C. 20549

Attention: Jeffrey P. Riedler

Re:
Inotek Pharmaceuticals Corporation

Amendment No. 1. to Registration Statement on Form S-1

Filed November 21, 2014

File No. 333-199859

 Ladies and Gentlemen:

This letter is submitted on behalf of Inotek Pharmaceuticals Corporation (the “Company”) in response to
the November 25, 2014 comment letter (the “Comment Letter”) of the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) regarding the
Company’s Amendment No. 1 to Registration Statement on Form S-1 which was filed with the Commission on November 21, 2014 (the “Registration Statement”).

For reference purposes, the text of the Comment Letter has been reproduced herein with responses below each numbered comment. For your
convenience, we have italicized the reproduced Staff comments from the Comment Letter.

 The responses provided herein are based upon information provided
to Goodwin Procter LLP by the Company. In addition to submitting this letter via EDGAR, we are sending via Federal Express two (2) copies of this letter.

Capitalization, page 62

1.
Please expand your pro forma disclosures throughout the filing to explain why assuming that the Series AA redeemable convertible preferred stock will be converted into common stock is factually supportable. Your
disclosure on F-20 indicates that automatic conversion occurs only if the price per share in a firmly underwritten public offering is not less than $7.65. Refer to rule 11-02(b)(6) of Regulation S-X.

Response: In response to the Staff’s comment, the Company respectfully advises the Staff that prior to filing the next amendment to the
Registration Statement, the Company expects to receive the requisite consent to approve a new Company charter that removes the provision stating that

the automatic conversion occurs only if the price per share in a firmly underwritten public offering is not less than $7.65.

Notes to Consolidated Financial Statements

7. Equity

 2014 Stock Option and Incentive
Plan, page F-24

2.
Please refer to comment 2. It is unclear how you have sufficiently addressed the reasons for the differences between recent valuations of your common stock leading up to the IPO and the estimated offering price
considering the significant increase in the fair value from the August 28, 2014 issuance to the midpoint of your price range. Please revise your analysis to address the following items:

•

Quantify the impact of the fair value increase attributed to the top line results received in October 2014 from the Phase 2 trial in which patients received trabodenoson eye drops co-administered with latanoprost eye
drops;

•

Quantify the discount for lack of marketability and tell us how you determined that it was appropriate; and

•

Tell us how you determined that the probabilities of the three possible future scenarios for the Company were appropriate given the DRS was filed August 29, 2014 and the equity capital markets have been highly
receptive to early-stage biotechnology life sciences companies in 2014 as noted in your response.

 Response: In response to
the Staff’s comment, the Company respectfully advises the Staff that it is supplementally providing the Staff with a letter containing an updated estimated offering price range and responses to the Staff’s comment.

* * * *

 We and the Company
appreciate the Staff’s attention to the review of the matters discussed herein. Please do not hesitate to contact me at: (212) 813-8853 if you have any questions regarding this letter.

Sincerely,

/s/ Edwin M. O’Connor

Edwin M. O’Connor

Goodwin Procter LLP

cc:
David P. Southwell, President and Chief Executive Officer, Inotek Pharmaceuticals Corporation

Mitchell S. Bloom, Goodwin Procter LLP